Study of FXS887 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called FXS887 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if FXS887 can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor that has grown or not responded to at least one prior treatment.
- You must have at least one measurable tumor (as seen on scans).
- You must be able to care for yourself (ECOG performance status 0 or 1).
- You must have adequate organ and bone marrow function.
- If you are of childbearing age, you must agree to use reliable birth control during the study and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called FXB0871 in people with advanced solid tumors that have stopped responding to standard treatments or for whom no standard treatment exists. The goal is to see if the drug is safe and effective, and patients who enroll will receive close monitoring throughout the study.
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new oral drug called SIGX1094R for people with advanced solid tumors that have not responded to other treatments. The study will check if the drug is safe and how well it works, and it requires a tumor tissue sample to look for a specific marker.
This trial tests a new drug (SIM0686) in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and how it affects tumors that have a specific protein called FGFR2b on their surface.
This trial tests a new drug called DXC018 for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. The goal is to see if the drug can shrink or slow the growth of these tumors.
Hear when a new Solid Tumor Refractory to Conventional Treatment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.